＊No.692026/6/28 22:46報告>>68CVS Caremark deferred its formulary decision to the next review cycle, with the next opportunity expected on January 1, 2027. This is a coverage delay, not a change in Neffy’s clinical value.返信投資の参考になりましたか？はい2いいえ0
